India's GlaxoSmithKline Pharmaceuticals Ltd reported an 8.6% fall in its pre-tax profit for the fourth quarter on Wednesday, hurt by the government's curbs on pricing of some essential medicines.
Consolidated profit before tax dropped to 1.90 billion rupees ($23.23 million) for the quarter ended March 31, from 2.08 billion rupees a year earlier, the Indian unit of UK's GSK Plc said in an exchange filing.
Revenue from operations at the maker of Augmentin antibiotic and T-Bact ointment fell 2.7% to 7.87 billion rupees.
"A robust underlying volume growth was offset by the impact of National List of Essential Medicines (NLEM) 2022," the company said.
GlaxoSmithKline's Ceftum and T-Bact, used to treat bacterial infections, were included in the NLEM list, which mandates those medicines to be sold below a price ceiling set by a government pricing body.
In March, the company said the revenue share of drugs impacted by the pricing cap was at 42% so far in 2023, up from 33% in 2022.
From Adani Wilmar to Havells India: Q4 results to watch out for today
Buoyant tax collections cushion govt on fiscal front; ITR reforms likely
Capital gains tax should be rationalised; need simpler ITR form: Experts
Budget 2023: Income tax slabs changed under new tax regime. Details here
Old income tax regime vs new income tax regime: Which one is better?
Deepak Fertilisers' Q4 profit after tax declines 9% to Rs 257 crore
GlaxoSmithKline Pharma posts net profit at Rs 133 crore in Jan-Mar quarter
REC net profit grows 33% YoY to Rs 3,065.37 crore in Jan-Mar quarter
Whirlpool net profit down 24.6% YoY to Rs 63.7 crore in Jan-Mar quarter
Tilaknagar Industries Q4 net profit more than doubles to Rs 59 crore
The company plans to mitigate the impact of the price caps by boosting sales volumes of its Ceftum, T-Bact and Augmentin.
Separately, the company recommended a dividend of 32 rupees per share.
Shares of the drugmaker closed 0.43% higher before the results, compared with a 0.45% fall in the benchmark Nifty Pharma index.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)